The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

This is a plain language summary of 2 articles published in the Journal of Child and Adolescent Psychopharmacology. It describes a medication called serdexmethylphenidate/dexmethylphenidate, or SDX/d-MPH for short. SDX/d-MPH is marketed under the name Azstarys®. It is in capsule form taken by mouth once a day in the morning and meant for treating patients aged 6 years and older with attention-deficit/hyperactivity disorder, commonly referred to as ADHD. This summary focuses on studies that were done in children and adolescents aged 6 to 12 years with ADHD. The study results showed how SDX/d-MPH reduced the symptoms of ADHD, how fast the medication began to work and for how long it worked in the study patients, as well as the medication’s safety during 1 year of treatmentThis Plain Language Summary of Publication article (PLSP) from Future Neurology looks at the effectiveness of SDX/d-MPH capsules on children and adolescents aged 6 to 12 years with ADHD.

Visit the site using the link to read the article.

This PLSP is based on two articles, both published in the Journal of Child and Adolescent Psychopharmacology. The first article is called, ‘A randomized, controlled laboratory classroom study of serdexmethylphenidate and d-methylphenidate capsules in children with attention-deficit/hyperactivity disorder.’

Visit the Mary Ann Liebert Publishers site using the link to read the article.

The second article is called ‘Safety and tolerability of serdexmethylphenidate/dexmethylphenidate capsules in children with attention-deficit/hyperactivity disorder: a 12-month, open-label safety study.’

Visit the Mary Ann Liebert Publishers site using the link to read the article.